NYSE:CLX • US1890541097
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CLOROX COMPANY (CLX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-04 | UBS | Maintains | Neutral -> Neutral |
| 2026-02-04 | Evercore ISI Group | Maintains | Underperform -> Underperform |
| 2026-02-04 | JP Morgan | Maintains | Neutral -> Neutral |
| 2026-02-04 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-23 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-16 | JP Morgan | Maintains | Neutral -> Neutral |
| 2026-01-14 | UBS | Maintains | Neutral -> Neutral |
| 2026-01-08 | TD Cowen | Maintains | Hold -> Hold |
| 2026-01-07 | Goldman Sachs | Maintains | Sell -> Sell |
| 2026-01-05 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-17 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-11-04 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-04 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-04 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-04 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-10 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-10-09 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-10-08 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-08 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-10-01 | Barclays | Maintains | Underweight -> Underweight |
| 2025-09-25 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-08 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-09-05 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-01 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.389B 3.97% | 7.093B -4.01% | 7.104B 0.16% | 6.567B -7.56% | 7.069B 7.64% | 7.323B 3.59% | 7.356B 0.45% | 7.61B 3.45% | 7.943B 4.38% | 8.255B 3.93% | 8.586B 4.01% | |
| EBITDA YoY % growth | 1.048B 11.97% | 1.156B 10.31% | 1.404B 21.45% | 1.282B -8.69% | 1.466B 14.35% | 1.541B 5.12% | 1.631B 5.84% | 1.7B 4.23% | 1.759B 3.47% | 1.837B 4.43% | 1.919B 4.46% | |
| EBIT YoY % growth | 812M 14.04% | 921M 13.42% | 1.185B 28.66% | 1.066B -10.04% | 1.232B 15.57% | 1.316B 6.82% | 1.427B 8.43% | 1.498B 4.98% | 1.522B 1.60% | 1.591B 4.53% | 1.663B 4.53% | |
| Operating Margin | 10.99% | 12.98% | 16.68% | 16.23% | 17.43% | 17.97% | 19.40% | 19.68% | 19.16% | 19.27% | 19.37% | |
| EPS YoY % growth | 5.09 23.84% | 6.18 21.41% | 7.73 25.08% | 5.98 -22.64% | 6.88 15.12% | 7.34 6.58% | 8.47 15.49% | 8.94 5.48% | 9.00 0.68% | 9.62 6.85% | 10.27 6.83% |
All data in USD
| Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.59 9.41% | 2.11 -26.47% | 1.41 65.57% | 1.62 16.53% | 1.71 7.99% | 2.17 2.68% | 1.59 12.67% | 1.71 5.80% | 1.79 4.74% | 2.33 7.67% |
| Revenue Q2Q % growth | 1.689B 1.26% | 1.748B -12.07% | 1.636B 14.49% | 1.704B 1.85% | 1.725B 2.13% | 1.812B 3.66% | 1.721B 5.20% | 1.761B 3.35% | 1.772B 2.72% | 1.884B 3.97% |
| EBITDA Q2Q % growth | 335.3M -17.00% | 422.94M -35.03% | 300.89M 71.94% | 335.06M -3.16% | 348.13M 3.83% | 430.97M 1.90% | 328.25M 9.09% | 350.2M 4.52% | 353.68M 1.59% | 452.02M 4.88% |
| EBIT Q2Q % growth | 280.67M 15.98% | 368.07M -14.80% | 248.07M 108.46% | 281.63M 19.84% | 296.12M 5.50% | 379.51M 3.11% | 279.58M 12.70% | 302.06M 7.25% | 304.83M 2.94% | 401.38M 5.76% |
All data in USD
27 analysts have analysed CLX and the average price target is 126.88 USD. This implies a price increase of 10.65% is expected in the next year compared to the current price of 114.66.
CLOROX COMPANY (CLX) will report earnings on 2026-05-04, after the market close.
The consensus EPS estimate for the next earnings of CLOROX COMPANY (CLX) is 1.59 USD and the consensus revenue estimate is 1.69B USD.
The consensus rating for CLOROX COMPANY (CLX) is 55.5556 / 100 . This indicates that analysts generally have a neutral outlook on the stock.